Endocrine connections · 2025
Relationship between Meteorin-like protein and type 2 diabetes mellitus: an update and meta-analysis.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Xie Jing, Jiang Yanhua, Yao Jiayi, Feng Bin, Sun Xin
Аннотация
BACKGROUND: Meteorin-like protein (Metrnl) is considered a novel adipokine, which plays an important role in the occurrence and development of type 2 diabetes mellitus (T2DM). In a previous meta-analysis, no significant difference in circulating Metrnl levels was found between T2DM patients and normal glucose tolerance individuals. However, these meta-analyses included limited studies, and more studies about Metrnl and T2DM were published recently. Therefore, the association between Metrnl and T2DM remains uncertain.
AIM: This study aimed to systematically and comprehensively update the relationship between circulating Metrnl levels and T2DM.
METHODS: A systematic search was conducted on the Web of Science, Wiley Online Library, PubMed, and Ovid databases using the terms 'type 2 diabetes mellitus' in combination with 'Metrnl'. Meta-analysis results were reported as standardized mean differences (SMDs) with corresponding 95% confidence intervals (CIs).
RESULTS: In total, 17 studies, including 649 patients with T2DM and 396 healthy controls, were included in the meta-analysis. We found that circulating Metrnl levels were lower in patients with T2DM than in healthy individuals (SMD: -0.47, 95% CI: (-0.98, 0.05); prediction interval: (-3.66, 2.73)). Moreover, serum Metrnl levels in patients with T2DM were significantly lower than in healthy individuals (SMD: -0.91, 95% CI: (-1.60, -0.22); prediction interval: (-5.03, 3.21)).
CONCLUSIONS: This study aimed to systematically and comprehensively update the relationship between circulating Metrnl levels and T2DM. A clearer understanding of the role of Metrnl in T2DM could facilitate the development of effective treatments.
AIM: This study aimed to systematically and comprehensively update the relationship between circulating Metrnl levels and T2DM.
METHODS: A systematic search was conducted on the Web of Science, Wiley Online Library, PubMed, and Ovid databases using the terms 'type 2 diabetes mellitus' in combination with 'Metrnl'. Meta-analysis results were reported as standardized mean differences (SMDs) with corresponding 95% confidence intervals (CIs).
RESULTS: In total, 17 studies, including 649 patients with T2DM and 396 healthy controls, were included in the meta-analysis. We found that circulating Metrnl levels were lower in patients with T2DM than in healthy individuals (SMD: -0.47, 95% CI: (-0.98, 0.05); prediction interval: (-3.66, 2.73)). Moreover, serum Metrnl levels in patients with T2DM were significantly lower than in healthy individuals (SMD: -0.91, 95% CI: (-1.60, -0.22); prediction interval: (-5.03, 3.21)).
CONCLUSIONS: This study aimed to systematically and comprehensively update the relationship between circulating Metrnl levels and T2DM. A clearer understanding of the role of Metrnl in T2DM could facilitate the development of effective treatments.